Russ Conroy

Articles

Talquetamab Plus Pomalidomide Maintains Deep, Durable Responses in R/R Multiple Myeloma

December 14th 2025

With longer median follow-up, talquetamab plus pomalidomide produced an ORR of 85.7% in patients with relapsed/refractory multiple myeloma in MonumenTAL-2.

Resection of MRI-Detected Disease Fails to Improve Recurrence Rates in Early Breast Cancer

December 11th 2025

Locoregional recurrence-free rates were similar in newly diagnosed breast cancer, irrespective of resection of MRI-detected disease.

Pembrolizumab Plus Radiation Yields Improvements in T-Cell Infiltration in Early Breast Cancer

December 11th 2025

Patients with early breast cancer who received pembrolizumab plus radiation therapy experienced significant improvements in T-Cell infiltration and promising pCR rates.

Ziftomenib Plus Venetoclax and Azacitidine Is Tolerable and Active in NPM1/KMT2A+ AML

December 8th 2025

Ziftomenib plus venetoclax and azacitidine was safe and effective in patients with relapsed/refractory AML harboring NPM1 mutations or KMT2A rearrangements.

Talquetamab Plus Teclistamab Displays Activity in R/R Multiple Myeloma With True EMD

December 8th 2025

Talquetamab plus teclistamab produced a high ORR and CR or better rate in relapsed/refracotry multiple myeloma with true extramedullary disease.

Survival in Induction Chemotherapy AML Studies May be Predictable by MRD

December 6th 2025

Future AML study analyses may focus on measurable residual disease to predict OS through non-intensive modern treatment backbones.

ctDNA Clearance With Adjuvant Therapy Is Associated With Improved DFS in CRC

October 25th 2025

Adjuvant therapy was associated with ctDNA clearance and improved DFS in patients with resectable stage I to IV CRC.

Zanzalintinib Plus Atezolizumab Improves OS in Previously Treated Metastatic CRC

October 20th 2025

Zanzalintinib plus atezolizumab demonstrate potential chemotherapy-free option in previously treated metastatic CRC.

Tarlatamab Improves OS vs Chemotherapy in SCLC, Regardless of Prior PD-(L)1 Therapy or CFI Duration

October 18th 2025

Findigs from DeLLphi-304 support the use of tarlatamab as a standard of care for all patients with second-line small cell lung cancer.

Adjuvant Nivolumab Generates Long-Term DFS Benefit in Resected MIUC

October 17th 2025

Five year follow up results from CheckMate 274 support adjuvant nivolumab as a standard of care for high-risk muscle-invasive urothelial carcinoma.

Sonrotoclax Plus Dexamethasone Generates Early Efficacy in R/R Myeloma

September 21st 2025

Sonrotoclax plus dexamethasone was well tolerated and produced early efficacy signals in relapsed/refractory multiple myeloma with t(11;14).

Co-Infusion of Anti-GPRC5D/Anti-BCMA Therapies Is Feasible, Yields Durable Responses in R/R Multiple Myeloma

September 19th 2025

Administering the anti-GPRC5D agent MCARH109 and anti-BCMA therapy MCARH125 in tandem was feasible and tolerable in relapsed/refractory multiple myeloma.

Arlo-Cel Demonstrates Tolerability, Efficacy in R/R Myeloma

September 19th 2025

Arlo-cel given as a single infusion drove efficacy and was safe in relapsed/refractory multiple myeloma.

Elranatamab Plus Daratumumab/Lenalidomide Generates Early Responses in Transplant-Ineligible, Newly Diagnosed Myeloma

September 17th 2025

Early and promising efficacy was shown with elranatamab added to daratumumab/lenalidomide in transplant-ineligible, newly diagnosed multiple myeloma.

Perioperative Pembrolizumab Plus Chemo Yields Improved Survival, Responses in Early-Stage Resectable NSCLC

September 8th 2025

Perioperative pembrolizumab demonstrated improved mPR, pCR, EFS, and OS in patients with early-stage resectable NSCLC and any nodal status.

SC Daratumumab Prolongs PFS in High-Risk Smoldering Myeloma

September 5th 2025

Subcutaneous daratumumab monotherapy demonstrated a 24-month PFS rate of 79.9% in patients with high-risk smoldering multiple myeloma.

Pembrolizumab/Lenvatinib Combination Produces Durable Responses in Advanced Non–Clear Cell RCC

July 18th 2025

Findings from the KEYNOTE-B61 trial demonstrate antitumor activity across histologic subtypes, including those with papillary and chromophobe disease.

Belzutifan Prolongs Quality-Adjusted Time Without Symptoms or Toxicity in Advanced RCC

July 18th 2025

Treatment with belzutifan increased the time without progression or toxicity vs everolimus in patients with advanced RCC.

Isa-KRd Yields Prolonged MRD Negativity vs KRd in Newly Diagnosed Myeloma

June 16th 2025

Isa-KRd significantly improved the 1-year MRD negativity rate compared with KRd alone in newly diagnosed patients with multiple myeloma.

JNJ’4496 Shows Preliminary Efficacy and Safety in Relapsed/Refractory LBCL

June 13th 2025

JNJ’4496 demonstrated an ORR of 100% in patients with relapsed or refractory large B-cell lymphoma who received 1 prior line of treatment.